Transforming cancer care: Neoadjuvant therapy and trials in melanoma care | 35 min 1

Neoadjuvant immunotherapy is transforming patient care in the field of melanoma. New research recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting is set to change melanoma treatment protocols globally, and likely to have significant impact on treatment for other cancers too.

In this podcast, A/Prof Matt Carlino leads an engaging discussion with MIA’s Prof Georgina Long AO, A/Prof Alex Menzies and A/Prof Alex van Akkooi as they discuss the pivotal results from the NADINA trial and how this will undoubtedly change the standard of care for Stage III melanoma patients. They also discuss the practical implications for implementing this treatment regime, including relevant patient populations, toxicity, impacts for surgery and future directions.

This podcast is suitable for Medical Oncologists, Surgical Oncologists, Pathologists, Researchers, GPs Oncology Nurses and other healthcare professionals.

Subscribe to our Melanoma Insights for Professionals podcasts via iTunes or Spotify or your favourite podcast app.


SPEAKERS
A/Prof Matteo Carlino
Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney
Declaration of Interest




Prof Georgina Long AO
Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney

Declaration of Interest


A/Prof Alexander Menzies
Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney
Declaration of Interest



A/Prof Alexander van Akkooi
Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney Declaration of Interest




HOST
Danielle Fischer
Education Program Manager, Melanoma Institute Australia
Declaration of Interest




PUBLICATIONS

• Blank C, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med 2024. DOI: 10.1056/NEJMoa2402604
• Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813-823.

• Podcast: Neoadjuvant immunotherapy: Revolutionising melanoma treatment
• Video: The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists
• Conference: 2024 Australasian Melanoma Conference

  

• Module1.1
  Transforming cancer care: Neoadjuvant therapy and trials in melanoma care | 35 min
  35 min